Itay & Beyond
Patient-derived lab grown brain tissue on a chip, to develop novel treatments for neurology and psyc
Company Overview
Snapshot
Founded in January 2021 by Nissim Perets, Itay & Beyond operates with 11–50 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative platform for neuropsychiatric drug discovery. In February 2025, the company was noted for its use of AI analysis with brain-on-a-chip technology to predict drug efficacy.
Business overview
Itay & Beyond is a pioneering biotech startup focused on revolutionizing neuropsychiatric drug discovery. The company leverages a platform that utilizes patient-derived, lab-grown brain tissue on a chip to develop novel treatments for neurological and psychiatric conditions. By integrating AI analysis with this brain-on-a-chip technology, Itay & Beyond aims to predict drug efficacy, accelerate testing, and expedite the development of more effective treatments, primarily serving the pharmaceutical and biotechnology sectors within the Health Tech & Life Sciences industry.
Strategic signal
In February 2025, Itay & Beyond gained attention for its innovative approach to drug discovery, utilizing AI analysis of a 'brain-on-a-chip' made from stem cells to predict drug efficacy for neuropsychiatric disorders. This development signals a significant advancement in preclinical testing, potentially shortening drug development timelines and improving success rates for treatments in neurology and psychiatry, which is a strong positive signal for investors in the biotech and pharmaceutical sectors.
Log in to access full profile ›Company Intelligence Q&A
- What is Itay & Beyond's core technology?
- Itay & Beyond's core technology involves patient-derived, lab-grown brain tissue on a chip, which is used to develop novel treatments for neurology and psychiatry. This platform integrates AI analysis to predict drug efficacy.
- When was Itay & Beyond founded?
- Itay & Beyond was founded in January 2021.
- Who is a key founder of Itay & Beyond?
- Nissim Perets is a co-founder and CEO of Itay & Beyond.
- What was a significant development for Itay & Beyond in early 2025?
- In February 2025, Itay & Beyond was highlighted for its use of AI analysis with a 'brain-on-a-chip' made from stem cells to predict drug efficacy for neuropsychiatric disorders, aiming to expedite testing and development.
- What market need does Itay & Beyond address?
- Itay & Beyond addresses the urgent need for more effective treatments in neuropsychiatry by revolutionizing drug discovery through its advanced platform.